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chamber.The concept of CTDI is still the basis for dosimetry at modern 
CT scanners, although the assessment of CTDI in phantoms has been 
the subject of much discussion and many revisions were required since 
its initial definition. A fundamental revision was for example needed 
when helical CT was introduced and the concept of pitch had to be 
taken into account. With the introduction of diagnostic wide CT 
beams and the introduction of cone beam computed tomography 
(CBCT) with CT scanners that are integrated with a linear accelerator 
a new problem arose. For these wide CT beams nor the CT dose 
phantoms nor the 100 mm long pencil ionization chamber were 
compatible with the at that time prevailing concept of CTDI. The 
problem was that the beam width of diagnostic wide beam scanners 
and CBCT scanners exceeds the lenght of the cylindrical CT phantoms 
(typically150 mm) and length of the pencil CT ionization chamber (100 
mm) (Geleijns etal.; Wen et al.). 
Solution for diagnostics wide cone beam CT scanners 
As a development to overcome the shortcomings described in the 
previous section, the proposed IEC 60601-2-44 international standard 
(Amendment1 of Edition 3) describes a two tiered approach to the 
definition of CTDI. The first tier is for beam widths ≤ 40 mm and uses 
the conventional definition of CTDI100. In the second tier for beam 
widths > 40mm, it is proposed to measure a reference value for CTDI 
in the standard CT dose phantoms, for anominal beam width of about 
20 mm. This value is then scaled up by the ratio of free in air 
measurements of CTDI for the wide beam condition and the reference 
condition. This approach is also followed in the IAEA Human Health 
Report 5 and is supported by the scientific work from Boone. 
Kilovoltage cone beam CT at the linac’s are a special case since at a 
large field of view the detector is shifted from the centered position, 
this may complicate the measurement of CTDI considerably. 
Assessment of patient dose for cone beam CT scans at the linac’s is 
also complicated. Monte Carlo calculations or measurements with 
anthropomorphic phantoms may be performed. A pragmatic approach 
may be to adhere to the methodology that is often used for diagnostic 
CTscanners, i.e. to use a body part specific conversion factor for 
calculating effective dose from dose-length product. 
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According to the MIRD formalism: 
 
Where  is the absorbed dose in target k from source h, Ãh is 
the cumulated activity in source h, and  is the mean absorbed 
dose per unit cumulated activity from source h to target k (also known 
as "S factor"). This, in theory, divides the calculation of the absorbed 
dose in 2 steps: determination of cumulated activity and computation 
of the S factor. 
When Ãh is obtained from a group of patients, or healthy volunteers, 
or from extrapolation from animal data, and when is obtained 
from a model (anthropomorphic phantom), the resulting absorbed 
dose is therefore suited for model dosimetry, i.e. to provide for 
estimates of the absorbed dose delivered to an hypothetical patient, 
rather than the patient that actually benefited from the nuclear 
medicine procedure. That kind of approach corresponds to the 
situation of radiopharmaceutical administration in a diagnostics 
context, where the injected activity is not supposed to induce 
deterministic effects. The ICRP tables give, for each 
radiopharmaceutical, an estimate of the absorbed dose delivered per 
MBq injected. These should be used in nuclear medicine departments: 
every patient should be given an estimate of the absorbed dose 
delivered during the procedure, even in a diagnostic context. 
In a therapeutic context, the delivered absorbed doses are within the 
range of appearance of deterministic effects. It is therefore important 
to increase the level of accuracy for the determination of the 
absorbed dose. A first step to achieve that goal is to assess the 
radiopharmaceutical uptake for every patient. This requires 
quantitative imaging and pharmacokinetics assessment procedures, 
and thus provides for a specific determination of Ãh.  
However, it is not always possible to derive specific values 
for . A possible means is to adjust model-based S factors in 
order to increase the specificity of the calculation. There are several 
means to achieve this, however one should keep in mind that the end-
result will still be a model-based absorbed dose computation (more or 
less realistic, as a function of the hypothesis adopted for adjusting 
model-based S factors to a given patient). 
Finally, whenever possible, in a therapeutic context, a full patient-
specific dosimetry should be performed. This requires patient-specific 
activity – and cumulated activity – determination, and computation of 
patient-specific S factors. This is the only way to obtain a real 
patient-specific absorbed dose assessment. The availability of CT-
based geometry definition combined with the spread of radiation 
transport modeling codes and the ever-growing computing power 
available now make this option a viable one in a clinical context. 
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Population doses from radiodiagnostic (x-ray and nuclear medicine) 
procedures in Europe were estimated for the first time in the recent 
DOSE DATAMED 2 (DDM2) project (www.ddmed.eu) launched by the 
European Commission. Data of 36 countries was collected to an 
established database.  
The results of the data collection and analysis lead to the following 
conclusions of the overall total collective effective doses in European 
countries:   
For x-ray procedures in EU-countries and EFTA countires (Norway, 
Iceland and Switzerland) the collective effective dose is 544700 
manSv, or 1,065 manSv per 1000 of population, resulting in a mean 
effective dose of 1,07 mSv per caput.  For all European countries 
included in the DDM2 survey the collective effective dose was 605010 
manSv, or 1,052 manSv per 1000 of population, resulting in a mean 
effective dose of 1,05 mSv per caput.    
For NM procedures in EU-countries and EFTA countries the collective 
effective dose is 30781 manSv, or 60,2 manSv per milion of 
population, resulting in a mean effective dose of 0,060 mSv per 
caput.  For all European countries included in the DDM2 survey the 
collective effective dose is 31336 manSv, or 54,5 manSv per million of 
